Daratumumab Darzalex®
The SHIKARI® Daratumumab portfolio combines quantitative free-drug measurement with qualitative anti-daratumumab antibody screening for method-controlled research.
Why Daratumumab is relevant to biological-drug monitoring research
Daratumumab has clinically important target biology, indication-specific dosing and measurable systemic exposure, making drug concentration and immunogenicity relevant research variables. Scientific source ↗ · EMA source ↗
Molecular Target & Structure
Daratumumab is a human IgG1κ monoclonal antibody directed against CD38, a surface protein highly expressed on plasma cells. Source ↗
Approved Indications
EMA-authorised uses are centred on multiple myeloma across defined treatment lines and combinations, with selected use in systemic AL amyloidosis. EMA source ↗
IV Weekly-Phase Exposure
FDA pharmacokinetic data under approved intravenous regimens show high concentrations during the initial weekly dosing phase:
Regulatory exposure values are regimen- and population-specific and are not therapeutic targets. Values vary with dose, timing, formulation and study population. This page is for RUO product information and does not provide clinical guidance.
Two verified Daratumumab research assays
Ligand-binding ELISA for quantitative analysis of free daratumumab in human serum or plasma.
Qualitative ELISA for reactive or non-reactive assessment of anti-daratumumab antibodies using assay-specific cut-off interpretation.
Verified Specifications at a Glance
| Kit | REF | Mode | Analyte | Sample | Volume | Time | Analytical output | Tests | Shelf life | Storage | Shipping |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SHIKARI® Q-DAR | DAR-FD-DAR | Quantitative | Free daratumumab | Human serum / plasma | 10 µL | 100 min | LOD 10 ng/mL; LOQ 10 ng/mL | 96 | 1 year | 2–8°C | 10–30°C |
| SHIKARI® S-ATDAR | DAR-QLS-DAR | Qualitative | Anti-daratumumab antibodies | Human serum / plasma | 20 µL | 140 min | Positive / negative | 96 | 1 year | 2–8°C | 10–30°C |
Analytical specifications are summarised from the current controlled IFUs and exact official product records. Standard curves are official illustrative images and must not be used for sample quantification. Follow the link on each assay card for the corresponding product record on matriksbiotek.com.
Match the assay to the research question
Daratumumab Literature and Product-Use Records
Planning a Daratumumab research study?
Matrix Biotek can help identify the appropriate Daratumumab assay and prepare regional quotation and delivery information.